Compare HCA Health Inc (HCA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Lam Research Corporation — how do they compare? HCA Health Inc trades at $410.3 (market cap $89.08B), while Lam Research Corporation trades at $325.64 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 4.4× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.76%). Which is the better fit depends on your goals.
| HCA | LRCX | |
|---|---|---|
Market Cap | $89.08B | $389.67B |
Sector | Health | Technology |
52-Week High | $545.13 | $433.33 |
52-Week Low | $361.32 | $97.03 |
Enterprise Value | $139.62B | $387.83B |
Dividend Yield | 0.76% | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Lam Research (LRCX) trades at $306.4, down 1.59% on the day, with a neutral technical signal. The company shows strong fundamentals, including a 31.27% net income margin and three consecutive quarterly EPS beats. Recent news highlights expansion into panel-level packaging and workforce development collaborations, supporting growth in the AI-driven semiconductor equipment sector.
Outlook remains positive with a consensus price target of $397.18, implying significant upside. Risks include competitive pressures from new entrants like SpaceX's Terafab and reliance on AI chip demand cycles. Analyst sentiment is strongly bullish with 78% buy ratings, but investors should monitor execution against high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
